Overexpression of clusterin promotes angiogenesis via the vascular endothelial growth factor in primary ovarian cancer

Fu,Yanxia; Lai,Yingrong; Wang,Qiongjuan; Liu,Xingyang; He,Weipeng; Zhang,Haihong; Fan,Chunyang; Yang,Guofen

doi:10.3892/mmr.2013.1436

Overexpression of clusterin promotes angiogenesis via the vascular endothelial growth factor in primary ovarian cancer

Authors:
- Yanxia Fu
- Yingrong Lai
- Qiongjuan Wang
- Xingyang Liu
- Weipeng He
- Haihong Zhang
- Chunyang Fan
- Guofen Yang
View Affiliations

Affiliations: Department of Gynecology, The First Affiliated Hospital of Sun Yat‑Sen University, Guangzhou, Guangdong 510080, P.R. China, Department of Pathology, The First Affiliated Hospital of Sun Yat‑Sen University, Guangzhou, Guangdong 510080, P.R. China, Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Published online on: April 23, 2013 https://doi.org/10.3892/mmr.2013.1436
Pages: 1726-1732

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Clusterin (CLU), a multifunctional glycoprotein, is ubiquitously produced in mammalian tissues. CLU has been shown to play significant roles in many of the biological behaviours of human tumors, such as cell proliferation, apoptosis, chemoresistance and angiogenesis. However, the relationship of CLU expression with angiogenesis in ovarian cancer has not been studied. A total of 275 epithelial ovarian tumors were obtained from archives of paraffin‑embedded tissues. Immunohistochemical (IHC) staining for CLU and vascular endothelial growth factor (VEGF) was performed on a tissue microarray (TMA) including 181 primary ovarian epithelial cancer, 40 borderline ovarian tumors and 54 ovarian cancer mesenteric metastasis samples. Of the 174 cases, overexpression of CLU and VEGF were detected in 107 (61.5%) and 109 (62.9%) cases of primary ovarian carcinoma, respectively. Of the 107 cases of primary ovarian carcinoma with overexpression of CLU, expression of VEGF was increased in 82 (75.2%) cases. However, in another 67 cases without CLU overexpression, overexpression of VEGF was observed in only 27 (24.8%) cases (P<0.05). Overexpression of CLU in epithelial ovarian cancer appears to be correlated with increased tumor angiogenesis, consistent with the established role of CLU as an oncogene in the biology of ovarian cancer. In the treatment of ovarian cancer, these two markers may be used in the selection of patients for targeted therapy.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics. CA Cancer J Clin. 62:10–29. 2012.
2	Yang GF, Li XM and Xie D: Overexpression of clusterin in ovarian cancer is correlated with impaired survival. Int J Gynecol Cancer. 19:1342–1346. 2009. View Article : Google Scholar : PubMed/NCBI
3	Trougakos IP and Gonos ES: Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol. 34:1430–1448. 2002. View Article : Google Scholar : PubMed/NCBI
4	Rizzi F and Bettuzzi S: Clusterin (CLU) and prostate cancer. Adv Cancer Res. 105:1–19. 2009. View Article : Google Scholar : PubMed/NCBI
5	Albert JM, Gonzalez A, Massion PP, Chen H, Olson SJ, Shyr Y, Diaz R, Lambright ES, Sandler A, Carbone DP, Putnam JJ, Johnson DH and Lu B: Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer. Cancer Epidemiol Biomarkers Prev. 16:1845–1851. 2007. View Article : Google Scholar : PubMed/NCBI
6	Pucci S, Bonanno E, Pichiorri F, Angeloni C and Spagnoli LG: Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene. 23:2298–2304. 2004. View Article : Google Scholar : PubMed/NCBI
7	Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M and Petito CK: Overexpression of clusterin in human breast carcinoma. Am J Pathol. 157:393–399. 2000. View Article : Google Scholar : PubMed/NCBI
8	Miyake H, Gleave M, Kamidono S and Hara I: Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology. 59:150–154. 2002. View Article : Google Scholar : PubMed/NCBI
9	Lau SH, Sham JS, Xie D, Tzang CH, Tang D, Ma N, Hu L, Wang Y, Wen JM, Xiao G, Zhang WM, Lau GK, Yang M and Guan XY: Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene. 25:1242–1250. 2006. View Article : Google Scholar : PubMed/NCBI
10	Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS and Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219:983–985. 1983. View Article : Google Scholar
11	Connolly DT, Olander JV, Heuvelman D, Nelson R, Monsell R, Siegel N, Haymore BL, Leimgruber R and Feder J: Human vascular permeability factor. Isolation from U937 cells. J Biol Chem. 264:20017–20024. 1989.PubMed/NCBI
12	Geva E and Jaffe RB: Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril. 74:429–438. 2000. View Article : Google Scholar : PubMed/NCBI
13	Ramakrishnan S, Subramanian IV, Yokoyama Y and Geller M: Angiogenesis in normal and neoplastic ovaries. Angiogenesis. 8:169–182. 2005. View Article : Google Scholar : PubMed/NCBI
14	Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G and Giavazzi R: Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res. 63:5224–5229. 2003.
15	Matei D, Kelich S, Cao L, Menning N, Emerson RE, Rao J, Jeng MH and Sledge GW: PDGF BB induces VEGF secretion in ovarian cancer. Cancer Biol Ther. 6:1951–1959. 2007. View Article : Google Scholar : PubMed/NCBI
16	Liao S, Liu J, Lin P, Shi T, Jain RK and Xu L: TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models. Clin Cancer Res. 17:1415–1424. 2011. View Article : Google Scholar : PubMed/NCBI
17	Cao Z, Fang J, Xia C, Shi X and Jiang BH: *************trans-3,4,5′-Trihydroxystibene inhibits hypoxia-inducible factor 1α and vascular endothelial growth factor expression in human ovarian cancer cells. Clin Cancer Res. 10:5253–5263. 2004.
18	Masoumi MS, Amini A, Morris DL and Pourgholami MH: Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev. 31:143–162. 2012. View Article : Google Scholar : PubMed/NCBI
19	Liu LZ, Hu XW, Xia C, He J, Zhou Q, Shi X, Fang J and Jiang BH: Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and P70S6K1 in human ovarian cancer cells. Free Radic Biol Med. 41:1521–1533. 2006. View Article : Google Scholar
20	Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 3:415–428. 2002.PubMed/NCBI
21	Hassan MK, Watari H, Han Y, Mitamura T, Hosaka M, Wang L, Tanaka S and Sakuragi N: Clusterin is a potential molecular predictor for ovarian cancer patient’s survival: targeting clusterin improves response to paclitaxel. J Exp Clin Cancer Res. 30:1132011.PubMed/NCBI
22	Ferrara N, Hillan KJ and Novotny W: Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 333:328–335. 2005. View Article : Google Scholar : PubMed/NCBI